Presentation

Osteo-D injectable solution: Each 1 ml ampoule contains Colecalciferol BP (as Vitamin D3) 200000 IU.

Osteo-D oral solution: Each 1 ml oral solution contains Colecalciferol BP (as Vitamin D3) 5 mcg (200 IU).

Osteo D Chewable Tablet: Each chewable tablet contains Colecalciferol BP (as Vitamin D3) 25 mcg (1000 IU)

Osteo-D 20000 IU soft gelatin capsule: Each soft gelatin capsule contains Cholecalciferol BP (as Vitamin D3) 20000 IU.

Osteo-D 40000 IU soft gelatin capsule: Each soft gelatin capsule contains Cholecalciferol BP (as Vitamin D3) 40000 IU.

Description

Vitamin D is essential for normal bone growth and development and to maintain bone density. It is also necessary for utilization of both Calcium and Phosphorus. Vitamin D acts as a hormone and increases reabsorption of Calcium and Phosphorus by the kidneys and increased bone turnover.

Indications

Breastfed infants who are not exposed to sunlight are unlikely to obtain adequate amounts of vitamin D from breast milk to satisfy their needs beyond early infancy because the vitamin D content of human milk is low (1-10 IU/250 mL). The vitamin D available to the infant during the first 6 months of life depends initially on the vitamin D status of the mother during pregnancy and later on the infant's diet and exposure to sunlight.

Vitamin D deficiency can result in rickets, a painful disease characterized by a softening of the bones and the growth plates. Dietary vitamin D is therefore recommended to correct for a lack of exposure to ultraviolet light fulfilling the required amount of Vitamin D.

Also, while the importance of vitamin D in infancy has been focused on protection from rickets, emerging research suggests that optimal vitamin D status may play a role in the protection against the development of other diseases.

Vitamin D is also important for the normal growth of the children and it helps to prevent rickets.

Dosage & Administration

Oral solution:

Colecalciferol (Vitamin D3) is recommended 5-10 mcg or 1-2ml (200-400 IU)/day or as directed by the physician.

Chewable tablet:

Cholecalciferol (Vitamin D3) is recommended 100 IU (1 tablet) daily, or as directed by physician. Take the medicine with food or within 1 hour after a meal. Place the tablet in mouth swallow after chewing.

Capsule:

Treatment of Vitamin D deficiency: 40000 IU/week for 7 weeks, followed by maintenance therapy 1000 IU/day.

Prevention of vitamin D deficiency: 20000 IU/Month.

Children:

Treatment of Vitamin D deficiency, 12-18 years: 20000 IU, once every 2 weeks for 6 weeks.

Prevention of Vitamin D deficiency, 12-18 years: 20000 IU, once every 6 weeks

Side Effects

Generally all nutritional supplements are considered to be safe and well tolerable. However, few side-effects can generally occur including hypercalcaemia syndrome or Calcium intoxication (depending on the severity and duration of hypercalcaemia), occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation with the administration of Colecaciferol.

Precautions

People with the following conditions should exercise caution when considering taking vitamin D supplements:

High blood Calcium or Phosphorus level

Heart problems

Kidney disease

People with the following conditions should exercise caution when considering taking vitamin D supplements:

High blood Calcium or Phosphorus level

Heart problems

Kidney disease

Vitamin D must be taken with adequate amounts of both Calcium and Magnesium supplementation. When Calcium level is low (due to

insufficient vitamin D and calcium intake), the body activates the parathyroid gland, which produces PTH (parathyroid hormone). This hormone kick starts vitamin D hormone production and assists removal of Calcium from the bones to be used in more important functions such as neutralizing body acidity.

Use in Pregnancy & Lactation

There is no evidence to suggest that vitamin D is teratogenic in humans even at very high doses. Colecalciferol should be used during pregnancy only if the benefits outweigh the potential risk to the fetus.

It should be assumed that exogenous Cholecalciferol passes into the breast milk. In view of the potential for hypercalcaemia in the mother and for adverse reactions from Cholecalciferol in nursing infants, mothers may breastfeed while taking Cholecalciferol, provided that the serum Calcium levels of the mother and infant are monitored. It should be assumed that exogenous Colecalciferol passes into the breast milk. In view of the potential for hypercalcaemia in the mother and for adverse reactions from Colecalciferol in nursing infants, mothers may breastfeed while taking Colecalciferol, provided that the serum Calcium levels of the mother and infant are monitored.

Drug Interaction

Since Cholecalciferol is one of the most important active metabolites of vitamin D, pharmacological doses of vitamin D and its derivatives should be withheld during treatment with Cholecalciferol to avoid possible additive effects and hypercalcaemia. Dietary instructions, especially concerning Calcium supplements, should be strictly observed and uncontrolled intake of additional Calcium-containing preparations avoided.

Concomitant treatment with a thiazide diuretic increases the risk of hypercalcaemia. Cholecalciferol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcaemia in such patients may precipitate cardiac arrhythmias. Magnesium-containing medicines (e.g. antacids) may cause hypermagnesemia and should therefore not be taken during therapy with Cholecalciferol by patients on chronic renal dialysis.

Over Dose

Acute symptoms: anorexia, headache, vomiting, constipation.

Chronic symptoms: dystrophy (weakness, loss of weight), sensory disturbances, possibly fever with thirst, polyuria, dehydration, apathy, arrested growth and urinary tract infections. Hypercalcaemia ensues, with metastatic calcification of the renal cortex, myocardium, lungs and pancreas.

Treatment: Immediate gastric lavage or induction of vomiting to prevent further absorption. Liquid paraffin should be administered to promote faecal excretion. Repeated serum calcium determinations are advisable. If elevated calcium levels persist in the serum, phosphates and corticosteroids may be administered and measures instituted to bring about adequate diuresis.

Commercial Pack

Osteo-D injectable solution: Each commercial box contains 1ampoule of 1ml solution.

Osteo-D oral solution: Each bottle contains 15 ml oral solution.

Osteo-D chewable tablet: Each box contains 5 Alu-Alu blister strips of 14 tablets.

Since Cholecalciferol is one of the most important active metabolites of vitamin D, pharmacological doses of vitamin D and its

derivatives should be withheld during treatment with Cholecalciferol to avoid possible additive effects and hypercalcaemia.

Dietary instructions, especially concerning Calcium supplements, should be strictly observed and uncontrolled intake of additional

Calcium-containing preparations avoided.

Concomitant treatment with a thiazide diuretic increases the risk of hypercalcaemia. Cholecalciferol dosage must be determined with

care in patients undergoing treatment with digitalis, as hypercalcaemia in such patients may precipitate cardiac arrhythmias.

Magnesium-containing medicines (e.g. antacids) may cause hypermagnesemia and should therefore not be taken during therapy with

Cholecalciferol by patients on chronic renal dialysis.